BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28576916)

  • 1. Fabry heterozygote mimicking multiple sclerosis.
    Yau WY; Fabis-Pedrini MJ; Kermode AG
    BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28576916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Misdiagnosis of multiple sclerosis in a female heterozygote with Fabry's disease.
    Berger JR
    Mult Scler Relat Disord; 2019 May; 30():45-47. PubMed ID: 30738278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fabry's disease (alpha-galactosidase-A deficiency): physiopathology, clinical signs, and genetic aspects].
    Germain DP
    J Soc Biol; 2002; 196(2):161-73. PubMed ID: 12360745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroke and Chronic Kidney Disease in Fabry Disease.
    Tapia D; Kimonis V
    J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of replacement enzyme therapy on central nervous system manifestations in Fabry's disease].
    Besson G; Vadot W; Guellerin J
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S257-9. PubMed ID: 21211675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: A case report.
    Germain DP; Bruneval P; Tran TC; Balouet P; Richalet B; Benistan K
    Eur J Med Genet; 2010; 53(2):111-2. PubMed ID: 20045092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fabry's disease revealed by stroke: a case report].
    Ronzière T
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S260-2. PubMed ID: 21211676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D313Y mutation in the differential diagnosis of white matter lesions: Experiences from a multiple sclerosis outpatient clinic.
    Becker J; Rolfs A; Karabul N; Berlit P; Kraemer M
    Mult Scler; 2016 Oct; 22(11):1502-1505. PubMed ID: 26993117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry Disease in Families With Hypertrophic Cardiomyopathy: Clinical Manifestations in the Classic and Later-Onset Phenotypes.
    Adalsteinsdottir B; Palsson R; Desnick RJ; Gardarsdottir M; Teekakirikul P; Maron M; Appelbaum E; Neisius U; Maron BJ; Burke MA; Chen B; Pagant S; Madsen CV; Danielsen R; Arngrimsson R; Feldt-Rasmussen U; Seidman JG; Seidman CE; Gunnarsson GT
    Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28798024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo mutation in a male patient with Fabry disease: a case report.
    Iemolo F; Pizzo F; Albeggiani G; Zizzo C; Colomba P; Scalia S; Bartolotta C; Duro G
    BMC Res Notes; 2014 Jan; 7():11. PubMed ID: 24398019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kidney in Fabry's disease.
    Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
    Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry disease: Review and experience during newborn screening.
    Hsu TR; Niu DM
    Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabry disease: a treatable lysosomal storage disorder.
    Phadke SR; Mandal K; Girisha KM
    Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Enzyme replacement therapy in Fabry's disease].
    Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
    Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.
    Takahashi N; Yokoi S; Kasuno K; Kogami A; Tsukimura T; Togawa T; Saito S; Ohno K; Hara M; Kurosawa H; Hirayama Y; Kurose T; Yokoyama Y; Mikami D; Kimura H; Naiki H; Sakuraba H; Iwano M
    Clin Nephrol; 2015 May; 83(5):301-8. PubMed ID: 25295576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
    Wang RY; Abe JT; Cohen AH; Wilcox WR
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.
    Lenders M; Weidemann F; Kurschat C; Canaan-Kühl S; Duning T; Stypmann J; Schmitz B; Reiermann S; Krämer J; Blaschke D; Wanner C; Brand SM; Brand E
    Orphanet J Rare Dis; 2016 May; 11(1):54. PubMed ID: 27142856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and Management of Fabry Disease in High-Risk Renal Disease Patients in Taiwan: A Single Center Study.
    Shih CY; You ZH; Tsai SF; Wu MJ; Yu TM; Chuang YW; Chen CH
    Transplant Proc; 2023 May; 55(4):788-791. PubMed ID: 37230899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.